Equipoise Remains a Major Consideration in the Ethical Evaluation of Phase 3 Randomized Controlled Trials Involving Precision Oncology Approaches in NSCLC

IF 21 1区医学 Q1 ONCOLOGY Journal of Thoracic Oncology Pub Date : 2024-11-01 DOI:10.1016/j.jtho.2024.07.004

Sarah Heynemann M.B.B.S., BMedSci, FRACP, MBioeth , Wendy Lipworth M.B.B.S., PhD , Sue-Anne McLachlan M.B.B.S., MSc, FRACP , Jennifer Philip M.B.B.S., GDipPallMed, MMed, PhD , Tom John M.B.B.S., PhD, FRACP , Ian Kerridge BA, BMed(Hons), MPhil(Cantab), FRACP, FRCPA

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

在对涉及 NSCLC 精准肿瘤学疗法的 3 期随机对照试验进行伦理评估时，Equipoise 仍是一个主要考虑因素

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Thoracic Oncology 医学-呼吸系统

CiteScore

36.00

自引率

3.90%

发文量

1406

审稿时长

13 days

期刊介绍： Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer,is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies.The readship includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.